Related Experiment Videos
["Lupus anticoagulant" in immune hyperthyroidism].
G Schuler1, A Alexopoulos, K Hasler
1Abteilung Klinische Endokrinologie, Medizinische Universitätsklinik und Poliklinik, Freiburg.
Deutsche Medizinische Wochenschrift (1946)
|October 5, 1990
Summary
A woman with autoimmune hyperthyroidism developed blood clotting issues due to acquired inhibitors. These inhibitors affected coagulation factors VIII and IX, impacting blood clotting times.
Area of Science:
- Hematology
- Endocrinology
- Immunology
Background:
- Autoimmune hyperthyroidism, also known as Basedow disease, can present with various systemic manifestations.
- Normal blood coagulation is essential for hemostasis, and disruptions can lead to bleeding or thrombotic events.
Observation:
- A 56-year-old woman with autoimmune hyperthyroidism initially had normal blood coagulation.
- She subsequently developed a prolonged partial thromboplastin time (PTT) and a reduced prothrombin time (Quick value).
Findings:
- Coagulation factor VIII activity decreased to 18% and factor IX activity to 16%.
- These reduced factor levels remained unchanged after the addition of normal plasma, indicating the presence of an acquired inhibitor.
- The findings suggest an acquired inhibitor of plasmatic coagulation was responsible for the observed hemostatic abnormalities.
Implications:
- Acquired coagulation inhibitors, initially termed lupus anticoagulants, can occur in autoimmune diseases beyond lupus erythematosus.
- This case highlights the importance of investigating coagulation abnormalities in patients with autoimmune conditions.
- Understanding these inhibitors is crucial for managing hemostatic complications in autoimmune diseases.